$CVRX

CVRx, Inc. (CVRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 CVRx Appoints John Landry as Chief Financial Officer Landry Brings Two Decades of Medtech and Public Company Finance Experience MINNEAPOLIS, Sept. 21, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on de

Binkowski Brent (CHIEF OPERATING OFFICER) purchased 26,223 shares of CVRx, Inc. (CVRX) at $2.91 on 2026-08-13.

CVRx (CVRX) reported Q2 2026 revenue of $15.7 million, up 16%, driven by U.S. heart failure sales. U.S. revenue rose 21% to $14.8 million; Europe revenue fell 31% to $0.9 million. Gross margin was 87%. Full-year 2026 revenue guidance was lowered to $58 million to $60 million. Management cited reimbursement headwinds, sales productivity strain, and a DOJ civil investigative demand.

CVRx, Inc. (CVRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 CVRx Announces Sales Leadership Transition Robert John to Depart as Chief Revenue Officer; Paul Verrastro Named Interim Head of Sales MINNEAPOLIS, August 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focuse

CVRx (CVRX) reported Q2 2026 revenue of $15.7M, up 16% from $13.6M a year earlier. U.S. revenue rose 21% to $14.8M, while Europe fell 31% to $0.9M. Gross profit increased to $13.7M and gross margin to 87%. Net loss narrowed to $14.0M. FY2026 revenue guidance is $58.0M to $60.0M.

CVRx, Inc. (CVRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CVRx Reports Second Quarter 2026 Financial and Operating Results MINNEAPOLIS, August 6, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromod

CVRx, Inc. (CVRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 tm2617208d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 June 8, 2026 Jared Oasheim joasheim@cvrx.com Re: Employment Transition Agreement Dear Jared, I want to thank you for your service to CVRx, Inc. (the “ Company ”). I understand you have chosen to transition from CVRx and a

CVRx announced the 25th successful Barostim implant at UNC Medical Center in Chapel Hill, highlighting the collaborative efforts of the medical team. This milestone follows a 20% increase in CVRx's first-quarter revenue and the commencement of patient enrollment for its BENEFIT-HF clinical trial, underscoring the company's growth and contributions to cardiac care.

Medtronic has made an all-cash offer to acquire CVRx Inc for approximately $300 million, bringing the heart-device specialist into focus for investors. The acquisition highlights the strategic value of CVRx's Barostim device, which treats heart failure and hypertension, and Medtronic's aim to expand its cardiovascular portfolio. The deal provides CVRx with access to Medtronic's global infrastructure and offers liquidity to shareholders, reflecting how larger companies seek innovation from smaller, publicly traded firms.

CVRx shares recovered after Humana announced a Medicare Advantage coverage policy for CVRx's Barostim cardiac implant. This news follows a post-earnings decline for the MedTech firm.